[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"emergency-contraception\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:emergency-contraception":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100528579","phase-4-etonogestrel-eng-implant-insertion-for-emergency-contraception-with-oral-levonorgestrel-lng-vs-placebo-100528579",false,"NCT06162611","Etonogestrel (ENG) Implant Insertion for Emergency Contraception With Oral Levonorgestrel (LNG) vs Placebo","Generating Evidence to Improve Same-day Etonogestrel (ENG) Implant Insertion for Emergency Contraception","Inclusion Criteria:\n\n* Between 18-35 years old\n* Unprotected intercourse within 72 hours\n* Biologically capable of pregnancy (intact uterus without prior sterilization surgery\n* Fluent in English and\u002For Spanish\n* Have a regular menstrual cycle (21-35 days)\n* Known last menstrual period (+\u002F- 3 days)\n* Working (cell) phone number\n* Willing to comply with the study requirements\n* Willing to abstain from any CYP3A4 inducer for 5 days\n\nExclusion Criteria:\n\n* Current pregnancy (+urine pregnancy test in clinic)\n* Breastfeeding\n* Contraindication to ENG or LNG based on CDC MEC\u002FSPR\n* Sterilization, hysterectomy, or has an IUD or contraceptive implant in place\n* Vaginal bleeding of unknown etiology\n* Previous use of EC in same cycle\n* Allergy to LNG or ENG\n* History of intolerance\u002F side effects with ENG Implant\n* Current (past 7 days) use of any CYP3A4 inducer\n* Plan to use any other steroid hormone in the next 4 weeks (testosterone, estrogen, progesterone)\n* Ended a pregnancy at or under 20 weeks gestational age within last 2 weeks\n* Ended a pregnancy over 20 weeks gestational age in last 6 weeks\n* Use of any injectable hormonal contraceptive (Depo-Provera) in the last 15 weeks\n* Use of any oral EC, contraceptive pills, patches, vaginal rings, or an IUD or Implant in the last 2 weeks",true,"FEMALE","18 Years","35 Years",{"count":21,"type":22},790,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","Intrauterine devices (IUDs) are highly effective to prevent pregnancy when used for emergency contraception (following unprotected intercourse in the last 3 days), but data are lacking for people who desire an etonogestrel (ENG) contraceptive implant in this situation. This proposal will identify the most effective way to start an implant for emergency contraception using a randomized controlled trial comparing pregnancy risk between those receiving the implant vs. the implant plus oral emergency contraception (EC). Data from this project will inform clinical practice and add another option, the implant, for those desiring a long acting, highly effective contraceptive method when they present for emergency contraception.",[28],"Emergency Contraception",[30,31,32],"contraception","etonogestrel implant","oral levonorgestrel","RECRUITING","2026-05-29",{"date":36,"type":37},"2026-06-02","ACTUAL",{"date":39,"type":37},"2023-11-06",{"date":41,"type":22},"2028-05-31",{"name":43,"class":44},"Lori Gawron","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":19,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":4},"100627489","phase-3-rct-assessing-pregnancy---piroxicam-for-ec-with-levonorgestrel-100627489","NCT07449299","Rct Assessing Pregnancy - Piroxicam for Ec With Levonorgestrel","RAPPEL","Inclusion Criteria:\n\n* Between 16-35 years old and desire LNG for EC\n* Unprotected intercourse within 72 hours\n* Biologically capable of pregnancy\n* Regular menstrual cycle 21-35 days long with known LMP +\u002F- 3 days\n* Working cell phone number that receives text messages (for Aim 3 participants phone with capability to download and use the Oova application and submit data)\n* Fluent in English and\u002For Spanish\n* Willing to comply with the study requirements including 1-month urine pregnancy test\n* No known contraindications to oral LNG or piroxicam - For secondary outcome assessing pregnancy risk for participants receiving study drug on day of ovulation or later - are currently using a menstrual cycle tracking application and can demonstrate according to the application that they are on the day of ovulation or post ovulation.\n\nExclusion Criteria:\n\n* Current pregnancy (+urine pregnancy test in clinic)\n\n  * Breastfeeding, post abortion or postpartum without resuming menstruation\n  * Use of hormonal contraception (including oral EC) within seven days of enrollment\n  * Use of NSAIDs (ibuprofen, naproxen, celecoxib, diclofenac, aspirin) in the prior week\n  * Highly effective contraception including permanent contraception (including partner with vasectomy), IUD, or contraceptive implant\n  * Allergy to LNG or piroxicam\n  * Desires UPA for EC\n\nHistory of stroke, myocardia infarction, ischemic heart disease, uncontrolled hypertension, congestive heart failure, peptic ulcer disease, renal or hepatic failure. Currently taking anticoagulants, corticosteroids, cyclosporine, lithium, methotrexate, or tacrolimus.","16 Years",{"count":55,"type":22},1458,[57],"PHASE3","This randomized controlled trial will test oral levonorgestrel + piroxicam vs. levonorgestrel + placebo for emergency contraception in a representative U.S. population that has higher pregnancy risk than in the prior study because of higher weights, different intercourse patterns, and different clinic accessibility. Data from this project will inform clinical practice in the U.S. and beyond for those desiring the most effective method of emergency contraception pills.",[28,60,61],"Contraception","COX-2 Inhibitor",[28,63,60],"Piroxicam","NOT_YET_RECRUITING","2026-02-26",{"date":67,"type":37},"2026-03-04",{"date":69,"type":22},"2027-03",{"date":71,"type":22},"2031-11",{"name":73,"class":44},"University of Utah"]